Evotec and PsychoGenics sign CNS drug discovery deal
No financial details released
Evotec is to partner PsychoGenics to offer CNS drug discovery solutions to pharmaceutical and biotech companies.
Under the agreement, the two companies will work together to give existing and new clients access to their complementary drug discovery platforms for the identification and development of new therapeutics targeting CNS disorders.
No financial details have been revealed.
Germany based Evotec has expertise in metabolic disease, CNS, pain, inflammation and oncology therapeutic areas.
PsychoGenics, located in Tarrytown, New York in the US, specialises in preclinical neurobiology applied to CNS and pain drug discovery and development. Its extensive capabilities coupled with its proprietary, high-throughput behavioural testing platforms allows the rapid screening and optimisation of compounds for CNS activity. These proprietary platforms are used for the characterisation of drugs, the phenotyping of disease models and the multi-dimensional testing of drugs in disease models.
Evotec’s chief operating officer Dr Mario Polywka said by bringing together the industry leading CNS drug discovery platforms of Evotec and PsychoGenics, their clients and partners would benefit through an increased probability of success and faster and more informed decision making in their drug discovery efforts.
